PCSK9 inhibitors in clinical practice: novel directions and new experiences.
暂无分享,去创建一个
C. Vlachopoulos | L. Rallidis | D. Tousoulis | E. Iliodromitis | E. Liberopoulos | M. Elisaf | I. Koutagiar | G. Anastasiou | I. Skoumas | E. Kiouri | N. Kosmas
[1] Diederick Grobbee,et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry , 2019, European journal of preventive cardiology.
[2] Odyssey Outcomes Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .
[3] G. Kolovou,et al. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). , 2018, Atherosclerosis.
[4] C. Ballantyne,et al. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. , 2018, Journal of clinical lipidology.
[5] B. Zafrir,et al. Lipid‐lowering therapy with PCSK9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic , 2018, Cardiovascular therapeutics.
[6] R. Rosenson,et al. Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials , 2018, Cardiovascular Drugs and Therapy.
[7] E. Stroes,et al. PCSK9 inhibitors in clinical practice: Delivering on the promise? , 2017, Atherosclerosis.
[8] L. Rallidis,et al. Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy. , 2017, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[9] M. Hlatky,et al. PCSK9 Inhibitors: Economics and Policy. , 2017, Journal of the American College of Cardiology.
[10] J. Kleijnen,et al. Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia , 2017, Journal of the American Heart Association.
[11] Alan S. Brown,et al. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. , 2017, Journal of clinical lipidology.
[12] R. Giugliano,et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial , 2017, JAMA cardiology.
[13] E. Sijbrands,et al. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. , 2017, Journal of clinical lipidology.
[14] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[15] J. Zamorano,et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk , 2016, European heart journal.
[16] S. Humphries,et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. , 2016, The lancet. Diabetes & endocrinology.
[17] L. Rallidis,et al. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. , 2016, Atherosclerosis.
[18] C. Ballantyne,et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.
[19] G. Watts,et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. , 2016, Journal of the American College of Cardiology.
[20] G. Kolovou,et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors , 2016, HORMONES.
[21] Dirk De Bacquer,et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. , 2015, Atherosclerosis.
[22] Lawrence A Leiter,et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.
[23] U. Laufs,et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. , 2013, Journal of the American College of Cardiology.
[24] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[25] F. Civeira,et al. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.